Knockdown MTDH Inhibits Glioma Proliferation and Migration and Promotes Apoptosis by Downregulating MYBL2

Junqi Fu1, Jun Peng1, Guolong Tu1

  • 1Department of Neurosurgery, Haikou People's Hospital, Haikou, Hainan Province 570208, China.

Mediators of Inflammation
|September 22, 2022
PubMed

Insights

Metadherin (MTDH) is overexpressed in glioma and drives tumor growth. Inhibiting MTDH reduces glioma cell proliferation and migration by downregulating MYBL2, suggesting MTDH as a potential therapeutic target for glioma.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer genetics

Background:

  • Glioma is a common malignant central nervous system tumor in adults.
  • The role of Metadherin/astrocyte-elevated gene-1 (MTDH) in glioma pathogenesis is not fully understood.
  • MTDH is implicated in various cancers, highlighting its potential oncogenic functions.

Purpose of the Study:

  • To elucidate the functional role of MTDH in glioma development.
  • To investigate the relationship between MTDH and MYBL2 expression in glioma.
  • To assess the therapeutic potential of targeting MTDH in glioma.

Main Methods:

  • Gene expression analysis using GEPIA, qRT-PCR, and Western Blot (WB).
  • Functional assays including cell proliferation (CCK-8), apoptosis (flow cytometry), migration, and invasion (Transwell assay).
  • In vitro knockdown of MTDH to evaluate downstream effects on MYBL2 and FoxM1 expression.

Main Results:

  • MTDH and MYBL2 were significantly overexpressed in glioma tissues compared to normal tissues.
  • Knockdown of MTDH reduced MYBL2 and FoxM1 expression in glioma cells.
  • MTDH inhibition suppressed glioma cell proliferation, migration, and invasion while promoting apoptosis.

Conclusions:

  • MTDH promotes glioma progression by upregulating MYBL2 expression.
  • Downregulation of MTDH inhibits glioma cell proliferation and metastasis.
  • MTDH represents a promising therapeutic target for clinical intervention in glioma treatment.